" class="no-js "lang="en-US"> Pavel Dřevínek, an Academic Researcher, on Services for Sepsis
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

May 11 2023

Pavel Dřevínek, an Academic Researcher, on Services for Sepsis

At the 33rd ECCMID event, we caught up with Pavel Dřevínek, an academic researcher at Charles University in Prague, who discusses the services his hospital offers for sepsis. He explains that sepsis is a serious condition that occurs when the body’s immune system overreacts to an infection, leading to organ failure and potentially life-threatening complications.

Dřevínek highlights the importance of early detection and treatment of sepsis, and notes that his hospital has developed a comprehensive sepsis protocol to ensure that patients receive prompt and effective care. This includes a range of diagnostic tests and interventions, such as blood cultures, antibiotics, and fluid resuscitation.

He also discusses the challenges involved in managing sepsis. To address these challenges, his hospital has established a multidisciplinary sepsis team that includes specialists from a variety of medical fields.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On